Nyrada, Inc. · ASX:NYR
Nyrada — Evans & Partners Small Cap Healthcare Conference 2026
25 slides from Nyrada's conference presentation, Sep 16, 2026
Slide 1: Building the Future of TRPC-based Therapies
personal use only Evans & Partners Small Cap Healthcare Conference Building the Future of TRPC-based Therapies 16 September 2026 ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer personal use only This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should not be Such forward-looking statements do not guarantee of future performance and involve known considered as an offer or invitation to subscribe for, or purchase any s
Slide 3: Investment Highlights
Investment Highlights personal use only Advancing first-in-class TRPC inhibitor with multiple near-term value catalysts Platform asset with Positive Phase I safety Near term Phase IIa High unmet need Strong IP & Uniquely Multiple near-term data supporting and pharmacokinetic safety and efficacy oppo
Slide 4: Nyrada and the Xolatryp Program
Nyrada and the Xolatryp® Program personal use only Nyrada is a world leading developer of TRPC-targeted therapies, providing exposure to an emerging and increasingly recognised therapeutic frontier › Nyrada Inc (ASX:NYR) is a clinical-stage biotechnology company developing a first-in-class small mol
Slide 5: Management
Management personal use only Experienced leadership across drug development and commercialisation Leadership Team Jasneet James Bonnar Benny Evison Alex Parmar Dimitri Burshtein Managing Ph.D Suchowerska Director of Investor Director & CEO Chief Scientific Ph.D Ph.D Relations and Officer Director of
Slide 6: Board of Directors
Board of Directors personal use only Experienced leadership across drug development and commercialisation Board Members John Moore Christopher Marcus Dr Rüdiger Dr Ian Dixon James Bonnar Non-Executive Cox Frampton Weseloh Non-Executive Managing Director Chairman Non-Executive Non-Executive Director
Slide 7: TRPC Channels: Clinical Landscape & Validation
TRPC Channels: Clinical Landscape & Validation personal use only Growing industry investment supports the emergence of TRPC therapeutics • Genetic validation and strong preclinical data have led to advancing clinical programs First TRPC Program to Reach Phase III across cardiovascular, kidney, neuro
Slide 8: Xolatryp Mechanism of Action
Xolatryp® Mechanism of Action personal use only Nyrada’s lead candidate Xolatryp® is a novel gatekeeper of calcium influx with broad therapeutic potential Overview Cardioprotection • Xolatryp® is a third generation TRPC 3/6/7 channel inhibitor TRPC3 TRPC6 TRPC7 • Highly differentiated, proven target
Slide 9: Xolatryp as a Platform Therapy
Xolatryp® as a Platform Therapy personal use only Highly focused multi-indication therapy addressing high unmet need in well-defined markets 1 Candidate Xolatryp® 3 Current Cardioprotection Oncology Neuroprotection Applications (secondary brain injury) Cardiac Reperfusion Injury Adjunct in Anthracyc
Slide 10: Diversified Pipeline
Diversified Pipeline personal use only Multiple compelling TRPC opportunities in indications of high unmet need Target Strategy and Upcoming Applications Pre-clinical Phase I Phase II Phase III Indication Catalysts • Safety review in H2 CY26 Cardiac Phase IIa • Topline data in Q3/Q4 CY27, Cardioprot
Slide 11: Xolatryp Phase I Clinical Trial
Xolatryp® Phase I Clinical Trial personal use only Primary endpoint met with all doses safe and well-tolerated, with no dose-limiting, or dose-related safety issues Trial Overview • Double-blinded, randomised, placebo-controlled Phase I study in 48 healthy volunteers • 36 received Xolatryp®, 12 rece
Slide 12: Xolatryp in Cardiac Reperfusion Injury
personal use only Xolatryp® in Cardiac Reperfusion Injury Well defined and uncontested $US3bn market opportunity
Slide 13: Heart Attack (STEMI)
Heart Attack (STEMI) personal use only STEMI results in a hyper-activation of TRPC channels Overview STEMI • Atherosclerotic plaque restricts blood flow to a region of the heart muscle resulting in Myocardial Infarction (MI) “Heart attack” • STEMI (ST-elevation myocardial infarction) is a blockage •
Slide 14: Current Standard Treatment for STEMI Heart Attack
Current Standard Treatment for STEMI Heart Attack personal use only Up to ~50% of heart injury may be caused by reperfusion, representing a major remaining therapeutic challenge Infarct size as a driver of heart failure Current Standard of Care for The Clinical Paradox from PCI risk and mortality ST
Slide 15: STEMI Heart Attack – Large Uncontested Market Opportunity
STEMI Heart Attack – Large Uncontested Market Opportunity personal use only US$3bn STEMI opportunity US Market Opportunity ~750K >80% ~600K US$5,000 US$3bn = STEMI¹ STEMI related PCI¹ Illustrative price² ✕ ✕ Total addressable Estimated PCI market in the US Annual STEMI Illustrative price procedures
Slide 16: Xolatryp Cardioprotective Function
Xolatryp® Cardioprotective Function personal use only Strong, consistent Cardioprotection across models of myocardial infarction Two preclinical studies evaluated Xolatryp® in myocardial ischemia-reperfusion (I/R) injury models. One assessed early arrhythmia events and biomarkers over 3 hours, the o
Slide 17: PROTECT-MI: Phase IIa Trial Design
PROTECT-MI: Phase IIa Trial Design personal use only Phase IIa Cardiac Reperfusion Injury clinical trial currently recruiting PROTECT-MI is a Phase IIa randomised, double-blind, placebo-controlled study 100 evaluable patients (placebo and drug evaluating Xolatryp® in STEMI patients undergoing PCI Si
Slide 18: Other Indications across Oncology & Neuroprotection
personal use only Other Indications across Oncology & Neuroprotection
Slide 19: Oncology – Antiproliferative
Oncology – Antiproliferative personal use only Xolatryp® enhances anthracycline anti-tumour efficacy as a novel adjunct oncology therapy Xolatryp® Enhances Standard Chemotherapy Efficacy and Safety ANTI-PROLIFERATIVE • Novel TRPC3/6/7 inhibitor targeting calcium-dependent tumour growth pathways Canc
Slide 20: Oncology – Cardioprotective
Oncology – Cardioprotective personal use only Xolatryp® demonstrates cardioprotection during anthracycline treatment Xolatryp® Enhances Standard Chemotherapy Efficacy and Safety CARDIOPROTECTION • Novel TRPC3/6/7 inhibitor targeting calcium dysregulation implicated in anthracycline-induced cardiac i
Slide 21: Neuroprotection
Neuroprotection personal use only Xolatryp® targets secondary injury following Ischemic Stroke and Traumatic Brain Injury Overview • Ischemic stroke and traumatic brain injury (TBI) trigger secondary injury pathways that drive ongoing neuronal damage • Excess intracellular Ca²⁺ is a key mediator of
Slide 22: Catalysts
Catalysts personal use only Multiple near-term milestones over the next 18 months 2H CY26 1H CY27 2H CY27 • PROTECT-MI Phase IIa execution: ongoing patient • PROTECT-MI Phase IIa execution: ongoing patient • Phase IIa PROTECT-MI topline data readout recruitment and site activations across Australian
Slide 23: Appendices
personal use only Appendices
Slide 24: Corporate Overview & Financial Snapshot
Corporate Overview & Financial Snapshot personal use only Key Details CDI Price Chart – Last 24 months Stock Code ASX:NYR $1.40 CDI Price (10 September 2026) A$0.72 Number of CDIs on Issue ~247.6m $1.20 Market Capitalisation (10 September 2026) ~A$178.3m $1.00 Cash Balance (30 June 2026) A$8.4m Numb
Slide 25: Key Links
Key Links personal use only • Cardioprotection • PROTECT-MI website - https://www.protect-mi.com • PROTECT-MI NIH Entry - https://bit.ly/4cB2fF9 • Phase IIa factsheet - https://bit.ly/4bcDlKj • Preclinical cardioprotection study 1a - https://bit.ly/4sigwMZ • Preclinical cardioprotection study 1b - h
Nyrada — Evans & Partners Small Cap Healthcare Conference 2026 on 6ix